Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorQilu Hospital of Shandong University
About this trial
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The history of acute myocardial infarction exceeds 3 months;
Symptoms and signs of heart failure have been stable for more than one month;
18 years old or more;
NYHA cardiac function classified as grade II~IV;
Disqualifiers
Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor;
Mechanical complications of myocardial infarction;
Unable to obtain primary outcome data.
Trial population
Patients with chronic heart failure with reduced ejection fraction after myocardial infarction
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Vericiguat Oral Tablet [Verquvo]
DrugVericiguat in addition to conventional treatment
Prescription Drugs
DrugConventional treatment only
Treatment groups
210 Participants
are divided into 2 treatment groupsGroup A: Vericiguat and conventional treatment2 interventions
Group B: Conventional treatment only1 intervention
Trial outcomes
Primary outcomes
1
LVEDVI=LVEDV/BSA
Changes of left ventricular end-diastolic volume index (LVEDVI) compared with baseline after 12 months
Time frame
From baseline to the end of 12-month treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Qilu Hospital of Shandong University
Lead sponsor
Jinan Central Hospital
Collaborator
Qianfoshan Hospital
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: